BCL2L1 and cancer: While Bcl6/Bcl-xL B cell immortalization was first described in IgG+ and IgM+ memory B cell populations from PBMCs from healthy donors, and similar B cell immortalization methods have recently been described in cancer settings and applied to naïve B cells, an extensive comparison of the same Bcl6/Bcl-xL B cell immortalization protocol across multiple B cell subsets, including chronic infection settings, has not been done (9, 21, 37).